KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Non Operating Income (2016 - 2025)

Eli Lilly (LLY) has disclosed Non Operating Income for 17 consecutive years, with -$108.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 1.99% year-over-year to -$108.3 million, compared with a TTM value of -$571.0 million through Dec 2025, down 160.73%, and an annual FY2025 reading of -$571.0 million, down 160.73% over the prior year.
  • Non Operating Income was -$108.3 million for Q4 2025 at Eli Lilly, up from -$133.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $321.1 million in Q1 2021 and bottomed at -$635.9 million in Q3 2021.
  • Average Non Operating Income over 5 years is -$60.8 million, with a median of -$84.0 million recorded in 2021.
  • The sharpest move saw Non Operating Income skyrocketed 436.35% in 2022, then tumbled 981.92% in 2025.
  • Year by year, Non Operating Income stood at -$77.3 million in 2021, then surged by 436.35% to $260.0 million in 2022, then plummeted by 53.35% to $121.3 million in 2023, then tumbled by 191.1% to -$110.5 million in 2024, then increased by 1.99% to -$108.3 million in 2025.
  • Business Quant data shows Non Operating Income for LLY at -$108.3 million in Q4 2025, -$133.1 million in Q3 2025, and -$90.6 million in Q2 2025.